SCHEMBL548788

SCHEMBL548788

Oc1cc(C23CC4CC(CC(C4)C2)C3)cc(C23CC4CC(CC(C4)C2)C3)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
GAA P10253 2/20 0.57
POLB P06746 1/20 0.57
GFER P55789 1/20 0.57
LMNA P02545 3/20 0.47
ALDH1A1 P00352 2/20 0.47
EPHX2 P34913 2/20 0.43
CNR2 P34972 7/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 2/20 0.39
USP2 O75604 1/20 0.38
THRB P10828 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
RAB9A P51151 1/20 0.38
RARA P10276 1/20 0.36
RARB P10826 1/20 0.36
RARG P13631 1/20 0.36
CNR1 P21554 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11642014 0.95 MEN1 (0.57) MEN1KMT2AGAAPOLBGFER
SCHEMBL25720237 0.82 MEN1 (0.45) MEN1KMT2AGAAPOLBGFER
SCHEMBL419753 0.79 MEN1 (0.59) MEN1KMT2AGAAPOLBGFER
SCHEMBL549877 0.78 MEN1 (0.53) MEN1KMT2AGAAPOLBGFER
SCHEMBL548727 0.78 MEN1 (0.63) MEN1KMT2AGAAPOLBGFER
SCHEMBL28094061 0.78 STS (0.46) MEN1KMT2AGAAPOLBGFER
SCHEMBL24522091 0.77 ALDH1A1 (0.63) MEN1KMT2AGAAPOLBGFER
SCHEMBL345588 0.77 LMNA (0.63) MEN1KMT2AGAAPOLBGFER
SCHEMBL22644196 0.77 LMNA (0.63) MEN1KMT2AGAAPOLBGFER
SCHEMBL24559531 0.77 LMNA (0.63) MEN1KMT2AGAAPOLBGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110614-B2 Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative IDEMITSU KOSAN CO., LTD. (JP) 2012-02-07 US disclosed
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2010-03-04 US disclosed
EP-2090563-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE ARCN1, RTN3, CHRNA3 MEN1 3412/4885KMT2A 3737/4885GAA 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.